西他列汀影响糖尿病大鼠中二肽基肽酶活性、胰岛素和血糖水平的基于机制的药物动力学/药效动力学模型研究

doi:10.5246/jcps.2018.06.038

摘要/Abstract

摘要：

二肽基肽酶(dipeptidyl peptidase-4, DPP-4)抑制剂通过阻碍某些肠促胰岛素的失活、进而增加胰岛素的分泌来发挥抗高血糖作用。本研究在链脲霉素诱导的2型糖尿病大鼠模型中, 使用高效液相色谱法测定单次口服300 mg/kg剂量下DPP-4抑制剂西他列汀的血药浓度, 并建立了一级吸收的一室药物动力学(pharmacokinetic, PK)模型, 用以描述西他列汀在大鼠体内的PK行为, 以及预测药效动力学(pharmacodynamic, PD)实验中各剂量下的相应血药浓度。随后测定了1、5、10 mg/kg西他列汀给药后糖尿病大鼠DPP-4活性、胰岛素和血糖水平数据, 建立基于机制的PK/PD模型。该模型以希尔氏方程表示西他列汀对DPP-4活性的抑制作用, 用间接效应模型描述胰岛素和血糖的变化过程。综上所述, 该模型阐释了西他列汀抗高血糖的作用机制, 还可以外推应用于其他物种或其他DPP-4抑制剂。

关键词: 西他列汀, 2型糖尿病, 大鼠, 二肽基肽酶, 胰岛素, 血糖, 基于机制的药物动力学/药效动力学模型

Abstract:

Dipeptidyl peptidase-4 (DPP-4) inhibitors exert their antihyperglycemic effects through repressing inactivation of certain incretin hormones and thus increasing insulin secretion and controlling glucose level. In this study, the plasma concentrations of sitagliptin, a potent DPP-4 inhibitor, after a single oral dose of 300 mg/kg in streptozotocin-induced type 2 diabetic rats were determined by HPLC. A one-compartment pharmacokinetic (PK) model with first order absorption was developed to describe the PK profile of sitagliptin, and the drug concentrations at the doses given in the pharmacodynamic (PD) study were simulated accordingly. The dynamic changes in DPP-4 activity, insulin concentration and blood glucose level in diabetic rats at doses of 1, 5 and 10 mg/kg were measured, and a mechanism-based PK/PD model was established subsequently. In this model, the inhibitory effect of sitagliptin on DPP-4 activity was demonstrated using the Hill’s function with direct link, and the downstream increase in insulin secretion and inhibition of glucose production were characterized using indirect response (IDR) models. This model interpreted the mechanism of antihyperglycemic action of sitagliptin, and may be modified and applied to other species or other agents in this class.

Key words: Sitagliptin, Type 2 diabetes mellitus, Rats, DPP-4, Insulin, Glucose, Mechanism-based pharmacokinetic/pharmacodynamic model

中图分类号:

R969.1

Supporting:

姚烨, 酒向飞, 王思媛, 卢炜, 周田彦. 西他列汀影响糖尿病大鼠中二肽基肽酶活性、胰岛素和血糖水平的基于机制的药物动力学/药效动力学模型研究[J]. 中国药学(英文版), 2018, 27(6): 371-382.

Ye Yao, Xiangfei Jiu, Siyuan Wang, Wei Lu, Tianyan Zhou. Mechanism-based pharmacokinetic/pharmacodynamic modeling of the effects of sitagliptin on DPP-4 activity, insulin and glucose in diabetic rats[J]. Journal of Chinese Pharmaceutical Sciences, 2018, 27(6): 371-382.

参考文献

[1] International Diabetes Federation. IDF Diabetes Atlas 8th Edition. 2017, 43-46. This article can be found online at https://www.idf.org/e-library/epidemiology-research/diabetes-atlas.html.

[2] DeFronzo, R.A.; Ferrannini, E.; Groop, L.; Henry, R.R.; Herman, W.H.; Holst, J.J.; Hu, F.B.; Kahn, C.R.; Raz, I.; Shulman, G.I.; Simonson, D.C.; Testa, M.A.; Weiss, R. Type 2 Diabetes Mellitus. Nat. Rev. Dis. Primers. 2015, 1, 15019.

[3] Drucker, D.J.; Nauck, M.A. The Incretin System: Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes. Lancet. 2006, 368, 1696-1705.

[4] Plosker, G.L. Sitagliptin: A Review of Its Use in Patients with Type 2 Diabetes Mellitus. Drugs. 2014, 74, 223-242.

[5] Herman, G.A.; Bergman, A.; Stevens, C.; Kotey, P.; Yi, B.; Zhao, P.; Dietrich, B.; Golor, G.; Schrodter, A.; Keymeulen, B.; Lasseter, K.C.; Kipnes, M.S.; Snyder, K.; Hilliard, D.; Tanen, M.; Cilissen, C.; De Smet, M.; de Lepeleire, I.; Van Dyck, K.; Wang, A.Q.; Zeng, W.; Davies, M.J.; Tanaka, W.; Holst, J.J.; Deacon, C.F.; Gottesdiener, K.M.; Wagner, J.A. Effect of Single Oral Doses of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, on Incretin and Plasma Glucose Levels after an Oral Glucose Tolerance Test in Patients with Type 2 Diabetes. J. Clin. Endocrinol. Metab. 2006, 91, 4612-4619.

[6] Langley, A.K.; Suffoletta, T.J.; Jennings, H.R. Dipeptidyl Peptidase IV Inhibitors and the Incretin System in Type 2 Diabetes Mellitus. Pharmacotherapy. 2007, 27, 1163-1180.

[7] Herman, G.A.; Stevens, C.; Van Dyck, K.; Bergman, A.; Yi, B.; De Smet, M.; Snyder, K.; Hilliard, D.; Tanen, M.; Tanaka, W.; Wang, A.Q.; Zeng, W.; Musson, D.; Winchell, G.; Davies, M.J.; Ramael, S.; Gottesdiener, K.M.; Wagner, J.A. Pharmacokinetics and Pharmacodynamics of Sitagliptin, an Inhibitor of Dipeptidyl Peptidase IV, in Healthy Subjects: Results from Two Randomized, Double-Blind, Placebo-Controlled Studies with Single Oral Doses. Clin. Pharmacol. Ther. 2005, 78, 675-688.

[8] Scheen, A.J. Pharmacokinetic and Pharmacodynamic Evaluation of Sitagliptin Plus Metformin. Expert Opin. Drug Metab. Toxicol. 2010, 6, 1265-1276.

[9] Agoram, B.M.; Martin, S.W.; van der Graaf, P.H. The Role of Mechanism-Based Pharmacokinetic-Pharmacodynamic (PK-PD) Modelling in Translational Research of Biologics. Drug Discov. Today. 2007, 12, 1018-1024.

[10] Murai, K.; Katsuno, T.; Miyagawa, J.; Matsuo, T.; Ochi, F.; Tokuda, M.; Kusunoki, Y.; Miuchi, M.; Namba, M. Very Short-Term Effects of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin on the Secretion of Insulin, Glucagon, and Incretin Hormones in Japanese Patients with Type 2 Diabetes Mellitus: Analysis of Meal Tolerance Test Data. Drugs R. D. 2014, 14, 301-308.

[11] Iwamoto, Y.; Taniguchi, T.; Nonaka, K.; Okamoto, T.; Okuyama, K.; Arjona Ferreira, J.C.; Amatruda, J. Dose-Ranging Efficacy of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, in Japanese Patients with Type 2 Diabetes Mellitus. Endocr. J. 2010, 57, 383-394.

[12] Zambrowicz, B.; Ding, Z.M.; Ogbaa, I.; Frazier, K.; Banks, P.; Turnage, A.; Freiman, J.; Smith, M.; Ruff, D.; Sands, A.; Powell, D. Effects of LX4211, a Dual SGLT1/SGLT2 Inhibitor, Plus Sitagliptin on Postprandial Active GLP-1 and Glycemic Control in Type 2 Diabetes. Clin. Ther. 2013, 35, 273-285 e7.

[13] Stepensky, D.; Friedman, M.; Raz, I.; Hoffman, A. Pharmacokinetic-Pharmacodynamic Analysis of the Glucose-Lowering Effect of Metformin in Diabetic Rats Reveals First-Pass Pharmacodynamic Effect. Drug Metab. Dispos. 2002, 30, 861-868.

[14] Jiu, X.F.; Shang, D.W.; Chen, Y.; Li, X.G.; Wan, X.M.; Zhou, T.Y.; Lu, W. A High Performance Liquid Chromatography Method for the Quantitative Deter-mination Assay of Sitagliptin in Rat Plasma and Its Application in Pharmacokinetics Study. J. Chin. Pharm. Sci. 2011, 20, 63-69.

[15] Hill, A. The Possible Effects of the Aggregation of the Molecules of Haemoglobin on Its Dissociation Curves. J. Physiol. 1910, 40 (supplement), 1115-1121.

[16] Dayneka, N.L.; Garg, V.; Jusko, W.J. Comparison of Four Basic Models of Indirect Pharmacodynamic Responses. J. Pharmacokinet. Biopharm. 1993, 21, 457-478.

[17] Rizza, R.A.; Mandarino, L.J.; Gerich, J.E. Dose-Response Characteristics for Effects of Insulin on Production and Utilization of Glucose in Man. Am. J. Physiol. 1981, 240, E630-639.

[18] Beconi, M.G.; Reed, J.R.; Teffera, Y.; Xia, Y.Q.; Kochansky, C.J.; Liu, D.Q.; Xu, S.; Elmore, C.S.; Ciccotto, S.; Hora, D.F.; Stearns, R.A.; Vincent, S.H. Disposition of the Dipeptidyl Peptidase 4 Inhibitor Sitagliptin in Rats and Dogs. Drug Metab. Dispos. 2007, 35, 525-532.

[19] Bergman, A.; Mistry, G.C.; Luo, W.L.; Liu, Q.; Stone, J.; Wang, A.; Zeng, W.; Chen, L.; Dilzer, S.; Lasseter, K.; Herman, G.A.; Wagner, J.A.; Krishna, R. Dose-Proportionality of a Final Market Image Sitagliptin Formulation, an Oral Dipeptidyl Peptidase-4 Inhibitor, in Healthy Volunteers. Biopharm. Drug Dispos. 2007, 28, 307-313.

[20] Ceriello, A.; Sportiello, L.; Rafaniello, C.; Rossi, F. DPP-4 Inhibitors: Pharmacological Differences and Their Clinical Implications. Expert Opin. Drug Saf. 2014, 13, S57-68.

[21] Kim, B.H.; Kim, S.E.; Kang, D.; Lim, K.S.; Kim, J.R.; Jang, I.J.; Shin, S.G.; Yoon, S.H.; Cho, J.Y.; Yu, K.S. Pharmacokinetic-Pharmacodynamic Modelling of Biomarker Response to Sitagliptin in Healthy Volunteers. Basic Clin. Pharmacol. Toxicol. 2013, 113, 113-125.

[22] Li, X.G.; Li, L.; Zhou, X.; Chen, Y.; Ren, Y.P.; Zhou, T.Y.; Lu, W. Pharmacokinetic/Pharmacodynamic Studies on Exenatide in Diabetic Rats. Acta Pharmacol. Sin. 2012, 33, 1379-1386.

[23] Bergman, A.J.; Stevens, C.; Zhou, Y.; Yi, B.; Laethem, M.; De Smet, M.; Snyder, K.; Hilliard, D.; Tanaka, W.; Zeng, W.; Tanen, M.; Wang, A.Q.; Chen, L.; Winchell, G.; Davies, M.J.; Ramael, S.; Wagner, J.A.; Herman, G.A. Pharmacokinetic and Pharmacodynamic Properties of Multiple Oral Doses of Sitagliptin, a Dipeptidyl Peptidase-IV Inhibitor: a Double-Blind, Randomized, Placebo-Controlled Study in Healthy Male Volunteers. Clin. Ther. 2006, 28, 55-72.

[24] Landersdorfer, C.B.; He, Y.L.; Jusko, W.J. Mechanism-Based Population Modelling of the Effects of Vildagliptin on GLP-1, Glucose and Insulin in Patients with Type 2 Diabetes. Br. J. Clin. Pharmacol. 2012, 73, 373-390.

[25] Gao, W.; Jusko, W.J. Modeling Disease Progression and Rosiglitazone Intervention in Type 2 Diabetic Goto-Kakizaki Rats. J. Pharmacol. Exp. Ther. 2012, 341, 617-625.